Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) was up 12.4% during mid-day trading on Tuesday . The company traded as high as $2.25 and last traded at $2.09, with a volume of 1,143,962 shares trading hands. The stock had previously closed at $1.86.

Separately, Zacks Investment Research lowered Aegerion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 25th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $13.21.

The firm’s market cap is $61.24 million. The company’s 50 day moving average is $1.61 and its 200-day moving average is $2.32.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/aegerion-pharmaceuticals-inc-aegr-trading-up-12-4.html

Aegerion Pharmaceuticals (NASDAQ:AEGR) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.34. The business earned $44.50 million during the quarter, compared to analyst estimates of $35.50 million. Aegerion Pharmaceuticals had a negative return on equity of 128.77% and a negative net margin of 80.76%. On average, equities analysts anticipate that Aegerion Pharmaceuticals Inc. will post ($3.44) earnings per share for the current year.

In other Aegerion Pharmaceuticals news, major shareholder Healthcare Master Fun Broadfin bought 276,000 shares of Aegerion Pharmaceuticals stock in a transaction dated Monday, September 12th. The shares were acquired at an average cost of $1.66 per share, with a total value of $458,160.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 4.60% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Sarissa Capital Management LP increased its position in Aegerion Pharmaceuticals by 2.7% in the second quarter. Sarissa Capital Management LP now owns 2,649,000 shares of the biopharmaceutical company’s stock valued at $3,947,000 after buying an additional 69,000 shares in the last quarter. Paloma Partners Management Co acquired a new stake in shares of Aegerion Pharmaceuticals during the second quarter valued at approximately $142,000. Jefferies Group LLC boosted its stake in shares of Aegerion Pharmaceuticals by 149.9% in the second quarter. Jefferies Group LLC now owns 745,150 shares of the biopharmaceutical company’s stock valued at $1,110,000 after buying an additional 447,027 shares during the last quarter. Spark Investment Management LLC boosted its stake in shares of Aegerion Pharmaceuticals by 10.1% in the second quarter. Spark Investment Management LLC now owns 586,400 shares of the biopharmaceutical company’s stock valued at $873,000 after buying an additional 53,600 shares during the last quarter. Finally, Ancora Advisors LLC acquired a new stake in shares of Aegerion Pharmaceuticals during the second quarter valued at approximately $114,000. 87.60% of the stock is currently owned by hedge funds and other institutional investors.

Aegerion Pharmaceuticals Company Profile

Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.

5 Day Chart for NASDAQ:AEGR

Receive News & Ratings for Aegerion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.